Standard BioTools Inc (NASDAQ: LAB) is -29.44% lower on its value in year-to-date trading and has touched a low of $0.92 and a high of $2.41 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The LAB stock was last observed hovering at around $1.25 in the last trading session, with the day’s gains setting it 0.41%.
Currently trading at $1.66M, the stock is 16.01% and 14.96% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.8 million and changing 1804624% at the moment leaves the stock -15.75% off its SMA200. LAB registered -27.43% loss for a year compared to 6-month loss of -36.50%. The firm has a 50-day simple moving average (SMA 50) of $1.1046 and a 200-day simple moving average (SMA200) of $1.5075.
The stock witnessed a 23.30% gain in the last 1 month and extending the period to 3 months gives it a 6.72%, and is 16.51% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.63% over the week and 8.23% over the month.
Standard BioTools Inc (LAB) has around 818 employees, a market worth around $482.38M and $169.69M in sales. Profit margin for the company is -78.24%. Distance from 52-week low is 38.04% and -47.30% from its 52-week high. The company has generated returns on investments over the last 12 months (-27.67%).
with sales reaching $39.83M over the same period.The EPS is expected to grow by 55.47% this year, but quarterly earnings will post -3.04% year-over-year. Quarterly sales are estimated to grow 7.06% in year-over-year returns.
197.0 institutions hold shares in Standard BioTools Inc (LAB), with institutional investors hold 74.23% of the company’s shares. The shares outstanding are 379.09M, and float is at 365.93M with Short Float at 4.42%. Institutions hold 73.09% of the Float.
The top institutional shareholder in the company is CASDIN CAPITAL, LLC with over 63.96 million shares valued at $113.21 million. The investor’s holdings represent 17.1782 of the LAB Shares outstanding. As of 2024-06-30, the second largest holder is VIKING GLOBAL INVESTORS LP with 58.65 million shares valued at $103.81 million to account for 15.7524 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 21.75 million shares representing 5.8424 and valued at over $38.5 million, while VANGUARD GROUP INC holds 4.2981 of the shares totaling 16.0 million with a market value of $28.33 million.
Standard BioTools Inc (LAB) Insider Activity
The most recent transaction is an insider sale by Kim Hanjoon Alex, the company’s Chief Financial Officer. SEC filings show that Kim Hanjoon Alex sold 1,428 shares of the company’s common stock on May 23 ’25 at a price of $0.94 per share for a total of $1344.0. Following the sale, the insider now owns 0.93 million shares.
Standard BioTools Inc disclosed in a document filed with the SEC on May 23 ’25 that Mackay Sean (SVP & Chief Business Officer) sold a total of 13,217 shares of the company’s common stock. The trade occurred on May 23 ’25 and was made at $0.94 per share for $12437.0. Following the transaction, the insider now directly holds 0.84 million shares of the LAB stock.
Still, SEC filings show that on May 23 ’25, Egholm Michael (President & CEO) disposed off 5,473 shares at an average price of $0.94 for $5150.0. The insider now directly holds 2,741,191 shares of Standard BioTools Inc (LAB).
